Korsana Biosciences, Inc. Common Stock
KRSA
17 hedge funds and large institutions have $4.1M invested in Korsana Biosciences, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 16 closing their positions.
5.9% less ownership
Funds ownership: 47.4% → 41.5% (-5.9%)
43% less funds holding
Funds holding: 30 → 17 (-13)
54% less capital invested
Capital invested by funds: $8.95M → $4.1M (-$4.85M)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
81% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$9.89K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$622 |
| 3 |
Morgan Stanley
New York
|
+$166 |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$83 |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$16 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$50.1K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$49.9K |
| 3 |
CG
Colony Group
Boston,
Massachusetts
|
-$44K |
| 4 |
Renaissance Technologies
New York
|
-$38K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$35.1K |
KRSA Hedge Fund Activity: Q2 2023 in Review
17 of the 6,384 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q2 2023, worth a combined $4.1M — down 54% from $8.95M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of KRSA and 3 opened new positions — a net loss of 13 holders — while 5 trimmed existing stakes and 2 added.
The largest buyer was Jane Street, opening a new position worth an estimated $9.89K. The largest seller was State Street, exiting entirely with an estimated $50.1K sold.
- 17 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q2 2023, down from 30 in Q1 2023.
- Funds reported $4.1M of Korsana Biosciences, Inc. Common Stock stock for Q2 2023, down 54% quarter-over-quarter.
- 3 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q2 2023 and 16 closed out, a net change of -13 holders.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q2 2023 was Jane Street, an estimated $9.89K added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q2 2023 was State Street, an estimated $50.1K sold.
Based on aggregated 13F filings for Q2 2023.